|
||
Brief Definitive Report |
samuel_wright{at}merck.com
| Abstract |
|---|
|
|
|---|
Key Words: atherosclerosis apolipoprotein E knockout germ-free animal Toll cholesterol
We have sought evidence for a causal role of infectious agents in atherosclerosis using the murine apolipoprotein (apo) E–/– (deficient) model. Because of the deficiency of apo E, these animals have high levels of plasma cholesterol and develop atherosclerosis with a reproducible time course 212223. In a first experiment, we bred the apo E–/– with a strain of mouse that is unable to respond to bacterial LPS, but found no alteration in the rate or extent of atherogenesis. In a second study, we developed a colony of germ-free apo E–/– animals. We observed no effect of gnotobiosis on the progress of atherosclerosis. We conclude that neither the response to infectious agents nor the presence of infectious agents themselves is absolutely necessary for atherogenesis.
Germ-free and control apo E–/– mice were generated and maintained at Taconic Farms. Sterility was verified by established procedures (standard operating procedure [SOP] no. G-LB-300.04).
For all mice in this study, offspring were weaned at 4 wk of age onto a high-fat Western-type diet containing 21.22% (g/100 g) fat, 17.01% protein, 48.48% carbohydrate, and 0.15% cholesterol (TD88137; Harlan Teklad) and maintained on the diet for the remainder of the study. Autoclaved food and water were provided ad libitum. The Institutional Animal Care and Use Committee of Merck Research Laboratories approved the animal use for experimentation, and all animals were cared for in accordance with the Guide for the Care and Use of Laboratory Animals (1996, National Research Council).
To measure aortic cholesterol and cholesteryl ester, mice were killed and gently perfused through the left ventricle with cold PBS with 5 mM EDTA. All branches and any adipose tissue connected to the aorta were removed, and each aorta was carefully excised from the aortic root to the right renal artery. The aortas were blotted dry, minced, and extracted with chloroform/methanol (2:1) according to the method used by Folch et al. 24. Total and free cholesterol in the aortic extracts were determined using an enzymatic fluorometric assay modified from previously described methods 2526, and data are expressed on a per aorta basis. Plasma cholesterol and triglyceride levels were determined using standard enzymatic kits (Sigma Chemical Co.).
For histology, mouse hearts were perfused in situ with PBS and removed with 1 mm of proximal aorta attached. The top half of the heart was embedded in O.C.T. embedding medium (Fisher Scientific) and prepared for cryosectioning. 6-µm sections were collected of the aortic root area, defined as having aortic valve leaflets present, and mounted on 10-well masked slides. Sections were stained with hematoxylin-phyloxine-saffron for morphology. Additional sections were immunolabeled with mAb L3T4 for CD4 or M1/70 for CD11b (PharMingen) using the horseradish peroxidase method with 3-3'-diamino benzadine as substrate.
![]()
Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Several types of studies have suggested that infectious agents may play a role in atherosclerosis and coronary heart disease (CHD). Atherosclerosis in chickens is exacerbated by infection with Marek's disease virus, a member of the herpes virus family 12, and numerous studies have suggested an association of viral pathogens such as CMV and bacterial pathogens such as Helicobacter and Chlamydia with human atherosclerosis 345. Recent data has drawn special attention to the association between Chlamydia pneumonia and CHD. Most 678 though not all 910 studies have found that patients with CHD are more likely to carry anti-Chlamydia antibodies than healthy subjects, and several studies have demonstrated that Chlamydia can be detected immunohistologically in >70% of atherosclerotic lesions, whereas it is virtually undetectable in undiseased arteries 5678. C. pneuomonia is a gram-negative bacteria that may produce persistent infection through intracellular growth in macrophages 11, a cell type that plays a dominant and necessary role in atherosclerotic lesions 1213. These observations have led to the hypothesis that Chlamydia may play a causal role in atherosclerosis and CHD 1415161718. This hypothesis is made plausible by studies on the association of Helicobacter pylori and duodenal ulcer 1920. This condition was originally thought to be caused by excess gastric acid and was treated by reducing or neutralizing acid. It is now clear that ulcers are most commonly caused by infection with H. pylori, and the most effective treatment involves antibiotics. In the same way, atherosclerosis is currently thought to be caused by excess plasma cholesterol and is treated by agents that reduce cholesterol levels. If Chlamydia or any other pathogen causes atherosclerosis, then a more effective treatment may be an antibiotic or vaccine.
![]()
Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Mice with the lpsd gene crossed onto a C57BL background (C57BL/10ScN) were the gift of Dr. Steven K. Chapes (Kansas State University, Manhattan, KS). These mice exhibited minimal increases in serum levels of TNF-
and IL-6 in response to intraperitoneal injection of 50 µg of LPS, whereas C57BL and apo E–/– animals exhibited >100-fold elevations in both (not shown). C57BL/10ScN mice were crossed with apo E–/– mice on a C57Bl/6 background (Jackson Laboratories). Apo E–/–/lpsdanimals were identified in the F2 progeny by the presence of plasma cholesterol levels >500 mg/dl and the absence of plasma elevations of TNF-
90 min after injection of 50 µg LPS.
![]()
Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
The time course of atherosclerogenesis in apo E–/– mice was followed by measuring aortic cholesteryl ester (Fig. 1), a parameter that tracks with histological progression of atherosclerosis (23; data not shown). To determine a role for gram-negative bacteria such as Chlamydia, we first used lpsd mice 27, animals with a congenital deficiency in responses to the principal inflammatory component of these bacteria, LPS (endotoxin). LPS is known to stimulate expression of cytokines (TNF, monocyte chemotactic protein 1 [MCP-1], and others), adhesion molecules (vascular cell adhesion molecule 1 [VCAM-1], intercellular adhesion molecule 1 [ICAM-1], β2 integrins), and enzymes (inducible nitric oxide synthetase [iNOS], matrix metalloproteinase 9 [MMP9]) observed in atherosclerotic lesions 28 and is a prime candidate to mediate possible proatherogenic effects of Chlamydia. lpsd mice fail to respond to LPS because of a deficiency in Toll-like receptor 4 (TLR-4 [29, 30]), a transmembrane protein with homology to the IL-1 receptor. lpsd animals were crossed with apo E–/– animals to yield doubly deficient animals. The inability of these animals to respond to LPS was verified by measurements of plasma TNF in response to LPS challenge, and their deficiency in apo E was verified by measurements of plasma cholesterol (described in Materials and Methods). We observed that development of atherosclerotic lesions in mice fed a high-fat Western-type diet was not altered by the deletion of TLR-4 (Fig. 1). Further studies showed that plasma cholesterol was also not affected by the absence of TLR-4 (data not shown). This result suggests that responses to gram-negative bacterial products are not critical for murine atherogenesis.
|
The progress of hyperlipidemia and atherogenesis in germ-free animals was compared with that of a second set of animals taken from the germ-free colony and reared with ambient pathogens. As expected, control apo E–/– animals exhibited extremely high levels of plasma cholesterol and moderately high triglyceride at both 22 and 32 wk of age (Fig. 2A and Fig. B). Germ-free animals showed an essentially identical plasma lipid profile, and lipid changes are thus unlikely to obscure effects of gnotobiosis on atherogenesis.
|
The similarity of atherogenesis in control and germ-free animals was confirmed by histologic examination of the aortic root in animals taken at the 22-wk time point. Well-developed lesions with necrotic cores, large foam cells, and fibrous caps were observed in both control and germ-free specimens (Fig. 3A and Fig. B), and neither quantitative nor qualitative differences could be detected in observations of either male or female lesions. A difference in aortic size reflecting the smaller body size of the germ-free animals 31 was readily detected histologically. T cells are found in human and murine atherosclerotic lesions 1223, suggesting activity of the adaptive immune system. We identified T cells by immunohistochemistry in both control and germ-free animals (Fig. 3C and Fig. D), indicating that pathogens are not required to drive the influx of T cells into atherosclerotic lesions.
|
| Discussion |
|---|
|
|
|---|
We wish to emphasize that the observations reported here relate to atherogenesis, not to plaque rupture, thrombus formation, or myocardial infarction. It is possible that infectious agents play an important role in one or more of these acute processes. Several current studies are seeking to define a role for bacterial infection in human CHD by studying endpoints such as myocardial infarction in patients randomized to placebo or antibiotic therapy of varying duration. The largest of these studies to report results thus far has failed to demonstrate a decline in cardiovascular events in the 6 mo after treatment with antibiotic 32. However, definitive results must await completion of larger, more extended trials.
Although our results suggest that pathogens do not serve as etiologic agents for atherosclerosis, they may still have a role in exacerbating the disease. Recent reports suggest that inoculation of atherosclerosis-prone mice with high doses of Chlamydia may cause an approximately twofold increase in the size of atherosclerotic lesions 3334. It is important to note that stresses such as infection provoke a set of physiological responses that are uniformly proatherogenic 353637. These include insulin resistance and hyperglycemia, elevation of plasma triglycerides, elevated white blood cell counts, elevated acute phase reactants (e.g., C-reactive protein and fibrinogen), and depression of high density lipoprotein (HDL) cholesterol levels. It is thus possible that infection may exacerbate atherosclerogenesis, and antibiotics may ameliorate atherogenesis not through the action of an etiologic agent, but through indirect effects on metabolism and known risk factors.
| Acknowledgments |
|---|
Submitted: 24 December 1999
Revised: 24 December 1999
Accepted: 17 January 2000
| References |
|---|
|
|
|---|
Fabricant C.G., Fabricant J., Litrenta M.M. & Minick C.R.. Virus-induced atherosclerosis, J. Exp. Med., 148, 1978, 335–340.
Fabricant C.G., Fabricant J., Minick C.R. & Litrenta M.M.. Herpesvirus-induced atherosclerosis in chickens, Fed. Proc., 42, 1983, 2476–2479.[Medline]
Epstein S.E., Speir E., Zhou Y.F., Guetta E., Leon M. & Finkel T.. The role of infection in restenosis and atherosclerosisfocus on cytomegalovirus, Lancet, 348Suppl.1996, 13–17.[Medline]
Patel P., Mendell M.A., Carrington D., Strachan D.P., Leatham E., Molineaux N., Levy J., Blakeston C., Seymour C.A. & Camm A.J.. Heart disease and cardiovascular risk factors, BMJ., 311, 1997, 711, .[Medline]
Danesh J., Collins R. & Peto R.. Chronic infections and coronary heart diseaseis there a link?, Lancet., 350, 1997, 430–436.[Medline]
Kuo C.C., Grayston J.T., Campbell L.A., Goo A., Wissler R.W. & Benditt E.P.. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old), Proc. Natl. Acad. Sci. USA., 92, 1995, 6911–6914.
Davidson M., Kuo C.C., Middaugh J.P., Campbell L.A., Wang S.P., Newman W.P. III, Finley J.C. & Grayston J.T.. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis, Circulation., 98, 1998, 628–633.
Campbell L.A., O'Brien E.R., Capuccio A.L., Kuo C.C., Wang S.P., Stewart D., Patton D.L., Cummings P.I. & Grayston J.T.. Detection of Chlamydia pneuomoniae TWAR in human coronary atherectomy tissues, J. Infect. Dis., 172, 1995, 585–588.[Medline]
Coles K.A., Plant A.J., Riley T.V., Smith D.W., McQuillan B.M. & Thompson P.L.. Lack of association between seropositivity to Chlamydia pneumoniae and carotid atherosclerosis, Am. J. Cardiol., 84, 1999, 825–828.[Medline]
Daus H., Ozbek C., Saage D., Scheller B., Schiefffer H., Pfreundschuh M. & Grause A.. Lack of evidence for a pathogenic role of Chlamydia pneumoniae and cytomegalovirus infection in coronary atheroma formation, Cardiology., 90, 1998, 83–88.[Medline]
Moazed T.C., Kuo C.C., Grayston J.T. & Campbell L.A.. Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse, J. Infect. Dis., 177, 1998, 1322–1325.[Medline]
Ross R.. Atherosclerosis – an inflammatory disease, N. Engl. J. Med., 340, 1999, 115–126.
Smith J.D., Trogan E., Ginsberg M., Grigaux C., Tian J. & Miyata M.. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E, Proc. Natl. Acad. Sci. USA., 92, 1995, 8264–8268.
Grayston J.T.. Does Chlamydia pneumoniae cause atherosclerosis?, Arch. Surg., 134, 1999, 930–934.
Campbell L.A., Kuo C.C. & Grayston J.T.. Chlamydia pneumoniae and cardiovascular disease, Emerg. Infect. Dis., 4, 1998, 571–579.[Medline]
Noll G.. Pathogenesis of atherosclerosisa possible relation to infection, Atherosclerosis., 140Suppl.1998, 3–9.
Gupta S. & Camm A.J.. Is there an infective aetiology to atherosclerosis?, Drugs Aging., 13, 1998, 1–7.[Medline]
Mehta J.L., Saldeen T.G. & Rand K.. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease, J. Am. Coll. Cardiol., 31, 1998, 1217–1225.
Taylor D.N. & Blaser M.J.. The epidemiology of Helicobacter pylori infection, Epidemiol. Rev., 13, 1991, 42–59.
NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. 1994. NIH Consensus Conference. Helicobacter pylori in Peptic Ulcer Disease. JAMA. 272:65–69.
Plump A.S., Smith J.D., Hayek T., Aalto-Setala K., Walsh A., Verstuyft J.G., Rubin E.M. & Breslow J.L.. Sever hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells, Cell., 71, 1992, 343–353.[Medline]
Piedrahita J.A., Zhang S.H., Hagaman J.R., Oliver P.M. & Maeda N.. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells, Proc. Natl. Acad. Sci. USA., 89, 1992, 4471–4475.
Nakashima Y., Plump A.S., Raines E.W., Breslow J.L. & Ross R.. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree, Arterioscler. Thromb., 14, 1994, 133–140.
Folch J., Lees M. & Sloane Stanley G.A.. A simple method for the isolation and purification of total lipids from animal tissue, J. Biol. Chem., 226, 1957, 497–509.
Gamble W., Vaughn M., Kruth H.S. & Avigan J.. Procedure for determination of free and total cholesterol in micro- or nanogram amounts suitable for studies with cultured cells, J. Lipid Res., 19, 1978, 1068–1070.[Abstract]
Heider J.G. & Boyett R.L.. The picomole determination of free and total cholesterol in cells in culture, J. Lipid Res., 19, 1978, 514–518.[Abstract]
Vogel S.. Insights into the genetic and molecular basis of LPS responsiveness and macrophage differentiation, Beutler B.. Tumor Necrosis Factorsthe Molecules and Their Emerging Role in Medicine, 1992, 485–513, Raven Press, Ltd., New York.
Wright S.D.. Innate recognition of microbial lipids, Gallin J.I. & Snyderman R., InflammationBasic Principles and Clinical Correlates, 3rd ed, 1999, 525–535, Lippincott Williams and Wilkins, Philadelphia.
Poltorak A., He X., Smirnova I., Liu M.Y., Huffel C.V., Du X., Birdwell D., Alejos E., Silva M. & Galanos C.. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr micemutations in Tlr4 gene, Science., 282, 1998, 2085–2088.
Wright S.D.. Toll, a new piece in the puzzle of innate immunity, J. Exp. Med., 189, 1999, 605–609.
1984. The germ-free animal in biomedical research. In Laboratory Animal Handbooks 9. M.E. Coates and B.E. Gustafsson, editors. Laboratory Animals, Ltd., London. 100–108.
Anderson J.L., Muhlestein M.B., Carlquist J., Allen A., Trehan S., Nielson C., Hall S., Brady J., Egger M., Horne B. & Lim T.. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection, Circulation., 99, 1999, 1540–1547.
Hu H., Pierce G.N. & Zhong G.. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumonia, J. Clin. Invest., 103, 1999, 747–753.[Medline]
Moazed T.C., Campbell A., Rosenfeld M.E., Grayston J.T. & Kuo C.-C.. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice, J. Infect. Dis., 180, 1999, 238–241.[Medline]
Danesh J., Collins R., Appleby P. & Peto R.. Association of fibrogen, C-reactive protein, albumin, or leukocyte count with coronary heart diseasemeta-analyses of prospective studies, JAMA., 279, 1998, 1477–1482.
Pickup J.C., Matock M.B., Chusney G.D. & Burt D.. NIDDM as a disease of the innate immune systemassociation of acute-phase reactants and interleukin-6 with metabolic syndrome X, Diabetologia., 40, 1997, 1286–1292.[Medline]
Ingenbleek Y. & Bernstein L.. The stressful condition as a nutritionally dependent adaptive dichotomy, Nutrition., 15, 1999, 305–320.[Medline]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|